Songyun Ouyang

Songyun Ouyang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical Immunology
Verified
Journal Article
Closed access
TWTingting Wang
Tingting Wang
HLHongchun Liu
Hongchun Liu
LPLu Pei
Lu Pei
KWKaijuan Wang
Kaijuan Wang
CSChunhua Song
Chunhua Song
LDLiping Dai
Liping Dai

19 December 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YHYachang Huo
Yachang Huo
DWDan Wang
Dan Wang
SYShuangning Yang
Shuangning Yang
YXYujie Xu
Yujie Xu
GQGuohui Qin
Guohui Qin
YZYi Zhang
Yi Zhang
Background: Anti-programmed cell death 1 (PD-1) antibody combined with chemotherapy simultaneously is regarded as the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) by current clinical guidelines. Different immune statuses induced by chemotherapy considerably affect the synergistic effects of the chemo-anti-PD-1 combination. Therefore, it is necessary to determine the optimal timing of combination treatment administration. Methods: The dynamic immune status induced by chemotherapy was observed in paired peripheral blood samples of patients with NSCLC using flow cytometry and RNA sequencing. Ex vivo studies and metastatic lung carcinoma mouse models were used to evaluate immune activity and explore the optimal combination timing. A multicenter prospective clinical study of 170 patients with advanced NSCLC was performed to assess clinical responses, and systemic immunity was assessed using omics approaches. Results: PD-1 expression on CD8+ T cells was downregulated on day 1 (D1) and D2, but recovered on D3 after chemotherapy administration, which is regulated by the calcium influx-P65 signaling pathway. Programmed cell death 1 ligand 1 expression in myeloid-derived suppressor cells was markedly reduced on D3. RNA sequencing analysis showed that T-cell function began to gradually recover on D3 rather than on D1. In addition, ex vivo and in vivo studies have shown that anti-PD-1 treatment on D3 after chemotherapy may enhance the antitumor response and considerably inhibit tumor growth. Finally, in clinical practice, a 3-day-delay sequential combination enhanced the objective response rate (ORR, 68%) and disease control rate (DCR, 98%) compared with the simultaneous combination (ORR=37%; DCR=81%), and prolonged progression-free survival to a greater extent than the simultaneous combination. The new T-cell receptor clones were effectively expanded, and CD8+ T-cell activity was similarly recovered. Conclusions: A 3-day-delay sequential combination might increase antitumor responses and clinical benefits compared with the simultaneous combination.

7 October 2022 in Cancer Science
Verified
Journal Article
Open access
MLMan Liu
Man Liu
ZZZhigang Zhou
Zhigang Zhou
FLFenghui Liu
Fenghui Liu
MWMeng Wang
Meng Wang
YWYulin Wang
Yulin Wang
SOSongyun Ouyang
Songyun Ouyang
Computed tomography (CT), an efficient radiological technology, is used to detect lung cancer in the clinic. Carcinoembryonic antigen (CEA), a common tumor biomarker, is applied in the detection of various tumors. To highlight the advantages of two‐dimensional techniques and assist clinicians in optimizing lung cancer diagnostic schemes, we established a favorable model combining CT and CEA. In the study, univariate analysis was performed to screen independent predictors in a training cohort of 271 patients with malignant pulmonary nodules (MPNs) and 92 with benign pulmonary nodules (BPNs). Six machine learning–based models involving five CT predictors (mediastinal lymph node enlargement, lobulation, vascular notch sign, spiculation, and nodule number) and lnCEA were constructed and validated in an independent cohort of 129 participants (92 MPNs and 37 BPNs) by SPSS Modeler. A nomogram and the Delong test were generated by R software. Finally, the model established by logistic regression had highest diagnostic efficiency (area under the curve [AUC] = 0.912). Moreover, the diagnostic ability of the logistic model in the validation cohort (AUC = 0.882, 80.4% sensitivity, 75.7% specificity) was higher than that of the Peking University model (AUC = 0.712, 68.5% sensitivity, 70.3% specificity) and the Mayo model (AUC = 0.745, 62.0% sensitivity, 75.7% specificity). Interestingly, for the participants with intermediate (10‐30 mm) and CEA‐negative nodule, the model reached an AUC of 0.835 (72.3% sensitivity, 83.3% specificity). The AUC for the early lung cancer was as high as 0.822 with 67.3% sensitivity and 78.9% specificity. As a conclusion, this promising model presents a new diagnostic strategy for the clinic to distinguish MPNs from BPNs.

21 May 2023 in Clinica Chimica Acta
Verified
Journal Article
Open access
YFYifei Fang
Yifei Fang
JSJiao Su
Jiao Su
BZBinglu Zhang
Binglu Zhang
CZChunling Zhao
Chunling Zhao
LJLongtao Ji
Longtao Ji
SOSongyun Ouyang
Songyun Ouyang
As many as 90% of patients with obstructive sleep apnea (OSA) may be undiagnosed. It is necessary to explore the potential value of autoantibodies against CRP, IL-6, IL-8 and TNF-α in the diagnosis of OSA. ELISA was performed to detect the level of autoantibodies against CRP, IL-6, IL-8 and TNF-α in sera from 264 OSA patients and 231 normal controls (NCs). The expression level of autoantibodies against CRP, IL-6 and IL-8 in OSA were significantly higher than that in NC while the level of anti-TNF-α was lower in OSA than that in NC. The per SD increment of anti-CRP, anti-IL-6 and anti-IL-8 autoantibodies were significantly associated with a 430%, 100% and 31% higher risk for OSA, respectively. The AUC of anti-CRP was 0.808 (95% CI: 0.771-0.845) when comparing OSA with NC, while the AUC increased to 0.876 (95% CI: 0.846-0.906) combining four autoantibodies. For discrimination of severe OSA versus NC and non-severe OSA versus NC, the AUC for four autoantibodies combination was 0.885 (95% CI: 0.851-0.918) and 0.876 (95% CI: 0.842-0.913). This study revealed the association between autoantibodies against inflammatory factors and OSA, and the combination of autoantibodies against CRP, IL-6, IL-8 and TNF-α may function as novel biomarker for monitoring the presence of OSA.

16 May 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
YFYifei Fang
Yifei Fang
JSJiao Su
Jiao Su
CZChunling Zhao
Chunling Zhao
YMYang Meng
Yang Meng
BWBeilei Wei
Beilei Wei
SOSongyun Ouyang
Songyun Ouyang
Background: Due to the significant role of dyslipidemia, cardiovascular diseases (CVDs) are very common in obstructive sleep apnea (OSA). Nontraditional lipid indices are considered to be a better predictive index for cardiovascular risk. Nevertheless, the association between nontraditional lipid profiles and the severity of OSA is not clear.Methods: A retrospective study was proceeded on 635 patients. Subjects were diagnosed with OSA through polysomnography (PSG). The association between severe OSA and nontraditional lipid profiles [triglyceride (TG)/high‐density lipoprotein cholesterol (HDL‐C) ratio, total cholesterol (TC)/HDL‐C ratio, low‐density lipoprotein cholesterol (LDL‐C)/HDL‐C ratio, non‐high‐density lipoprotein cholesterol (non‐HDL‐C), atherogenic index (AI), and lipoprotein combine index (LCI)] was examined by utilizing the restricted cubic spline and multivariate logistic regression analysis.Results: All nontraditional lipid indices had positive relationships with the severity of OSA. By multivariable adjustment, the per SD increment of the TG/HDL‐C, TC/ HDL‐C, LDL‐C/HDL‐C, non‐HDL‐C, AI, and LCI were significantly associated with 88%, 50%, 42%, 40%, 50%, and 125% higher risk for severe OSA respectively. Compared with the lowest tertiles, the adjusted ORs (95% CI) were 2.42 (1.57–3.75), 2.39 (1.53–3.73), 2.35 (1.52–3.64), 1.86 (1.21–2.86), 2.39 (1.53–3.73), and 2.23 (1.43–3.48) for the top tertiles of TG/HDL‐C, TC/ HDL‐C, LDL‐C/HDL‐C, non‐HDL‐C, AI, and LCI respectively.Conclusion: All nontraditional lipid indices had positive relationship with the severity of OSA. In addition, TG/HDL‐C, TC/HDL‐C, and AI had better performance than the other nontraditional lipid indices for predicting severe OSA. These findings could help to determine the risk of cardiovascular diseases and improve the dyslipidemia management of OSA patients.

1 January 2022 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
JSJiao Su
Jiao Su
YFYifei Fang
Yifei Fang
YMYang Meng
Yang Meng
CZChunling Zhao
Chunling Zhao
YLYanjun Liu
Yanjun Liu
SOSongyun Ouyang
Songyun Ouyang
Background: Obstructive sleep apnea (OSA) and/or gastroesophageal reflux (GER) may be the contributors to chronic cough in patients with OSA and concomitant GER. This study aimed to explore whether continuous positive airway pressure (CPAP), antireflux treatment and lifestyle modifications improve chronic cough in patients with OSA and concomitant GER. Methods: Patients with OSA and concomitant GER who also experienced chronic cough were enrolled, and were divided into two groups. Patients who were treated with general treatment (antireflux treatment and lifestyle modifications) as the control group, and patients who were treated with CPAP and general treatment as the treatment group. Effects of different treatments on chronic cough were assessed, and the association among chronic cough, GER and OSA was evaluated by Pearson’s correlation analysis. Results: The Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale were better in the treatment group after 1 week of treatment; further, the improvement became stronger with the duration of therapy. The gastroesophageal reflux disease questionnaire, visual analog scale (VAS) for cough, and daytime and nighttime cough symptom scores significantly improved in both groups after treatment, whereas this improvement was more significant in the treatment group. Significant associations between the apnea-hypopnea index (AHI) and VAS, weak acid reflux and VAS, and weak acid reflux and AHI were observed. Conclusion: CPAP improved the symptoms of chronic cough and GER in patients with OSA and concomitant GER. AHI and weak acid reflux may be important factors affecting the therapeutic effect of chronic cough in patients with OSA and concomitant GER.